Therapy Areas: Oncology
Regeneron Pharmaceuticals enters into collaboration and licensing agreement with CytomX Therapeutics
18 November 2022 -

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a US-based biotechnology company, announced on Thursday that it has entered into a collaboration and licensing agreement with California-based CytomX Therapeutics, Inc. (NASDAQ: CTMX), a clinical-stage, oncology-focused biopharmaceutical company.

The collaboration is aimed at developing conditionally-activated investigational bispecific cancer therapies using CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform. It is intended to implement CytomX's biologic masking strategies to produce investigational Regeneron bispecifics that remain inactive until activated by proteases in the tumour microenvironment.

According to the contract, both companies will partner on the discovery activities to find and validate conditionally active bispecific antibodies. Regeneron will manage funding preclinical and clinical development and commercialisation activities, while CytomX will receive an upfront payment of USD30m and be eligible for future target nomination payments and preclinical, clinical, and commercial milestones of up to USD2bn. CytomX also has the option to receive tiered global net sales royalties.